AdvertisementSupported byBusiness BriefingBy ReutersThe Food and Drug Administration said it had approved Portrazza from Eli Lilly, in combination with two forms of chemotherapy, to treat patients with advanced squamous nonsmall cell lung cancer, the most common type of lung cancer. The treatment will need to carry a “boxed warning” that flags potential fatal risks, including cardiac arrest and sudden death. A 1,093-patient clinical trial showed that patients who received Portrazza, along with the chemotherapy drugs gemcitabine and cisplatin, survived an average of 11.5 months compared with 9.9 months for those who received only chemotherapy treatments. Advertisement